SAIHEAT Purchases $1.5 Million of Bitcoin
SINGAPORE, Nov. 21, 2024 (GLOBE NEWSWIRE) — SAIHEAT Limited (f/k/a SAI.TECH Global Corporation) (“SAIHEAT” or the “Company”) (NASDAQ: SAIH, SAITW), […]
Xumo and PubMatic Partner to Expand Programmatic Advertising
PHILADELPHIA and REDWOOD CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) — Xumo, a streaming platform joint venture between Comcast and […]
Capital Bank Named One of the Best Banks to Work for in 2024
ROCKVILLE, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) — Capital Bank has been named one of American Banker’s 2024 Best Banks […]
Vita Coco is Treating Fans This Holiday Season with 12 Days of Treats-mas Giveaway
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) — The Vita Coco Coconut Company (NYSE: COCO) is making it easy for […]
Jeffs’ Brands Enters into a Patent Licensing Agreement to Market and Sell Photovoltaic Technology on Amazon
Tel Aviv, Israel, Nov. 21, 2024 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), […]
Intuitive Machines and Johns Hopkins APL Partner to Advance Safe, Secure, and Reliable Lunar Infrastructure
HOUSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) — Intuitive Machines, Inc. (Nasdaq: LUNR, LUNRW) (“Intuitive Machines”) (“Company”), a leading space exploration, […]
LM Funding America, Inc.’s Bitcoin Holdings Valued at $13.3 million in Monthly Update
TAMPA, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a […]
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative […]
Wix Reports Third Quarter 2024 Results
Strong performance of key product initiatives drove third consecutive quarter of bookings growth acceleration – now expect to exit 2024 […]
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes […]
